Nyxoah Sa · EURONEXT:NYXH
Nyxoah Sa — Investor Presentation (November 2023)
12 slides from Nyxoah Sa's investor presentation, November 2023
Slide 1: Nyxoah Investor Presentation
Nyxoah Investor Presentation November 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Please read the following before continuing. This presentation has been prepared by the management of Nyxoah SA (the "Company"). It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or oth
Slide 3: Experienced Board and Management Team
Experienced Board and Management Team Robert Taub Olivier Taelman Loïc Moreau Founder, Chairman Chief Executive Officer Chief Financial Officer • Serial entrepreneur in the pharmaceutical and • Experienced Medtech leader • Experienced Finance leader medical fields • 7 years in pharmaceutical healthc
Slide 4: Nyxoah's Blueprint for Success
Nyxoah’s Blueprint for Success >$10bn US HGNS Market Opportunity with <5% Penetration and Established Reimbursement Genio® - A Breakthrough and Disruptive Hypoglossal Nerve Stimulation Solution Proof-of-Concept European Commercialization De-risked Pivotal Study with a US Launch in 2024 and CCC Label
Slide 5: Large and Underpenetrated Global OSA and HGNS Market Opportunity
Large and Underpenetrated Global OSA and HGNS Market Opportunity Worldwide Obstructive Sleep Apnea Prevalence Hypoglossal Nerve Stimulation Market Opportunity 936 Million >1 million eligible annually in key geographies • 936M individuals (30-69 year) are estimated to suffer from OSA 1 • US: 510,000
Slide 6: The Genio System: An innovative and unique solution
The Genio® System An innovative and unique solution • Mode of Action Hypoglossal nerve Genioglossus Maintaining Genio® system stimulation muscle contraction open airway • Genio System Components Implantable Stimulator Wearable Charging Unit 6 Commercially confidential. Not for distribution
Slide 7: Clinical Strategy Overview
Clinical Strategy Overview CE-Mark BLAST OSA – 27 patients • 2 publications • CE mark approval in 2019 Demonstrate long-term safety and efficacy EliSA – 110 patients • European study Implants completion – Q4 2023 • 5-year follow-up CCC indication expansion BETTER SLEEP – 42 patients • CCC and non-CC
Slide 8: Growing Body of Clinical & Real-life Evidence
Clinical Strategy Overview Growing Body of Clinical & Real-life Evidence AHI Responder Rates N=22 N=36 N=34 BLAST OSA CE Mark BLAST BETTER DREAM BETTER SLEEP CCC label – Europe OSA SLEEP ElISA Long term data – Europe @6 months @6 months @12 months DREAM FDA approval 50% 64% 65% ACCCESS CCC label – U
Slide 9: Genio Expected to Capture approx. 50% Market Share
Genio Expected to Capture approx. 50% Market Share Independent 25 Clinician Survey Guidepoint Survey • Sample size – 25 clinicians • Physician Profile • 12 US ENTs + 4 German ENTs • Clinicians at least “somewhat familiar” with Genio and Inspire systems • 9 US Sleep Specialists • ENTs/Sleep Specialis
Slide 10: 2023 – 2024 Key Milestones
2023 – 2024 Key Milestones DREAM DREAM DREAM 34 patients DREAM CLINICAL All patients 12M data on abstract @ 12M data implanted 34 patients SLEEP 2023 Module 4 – Module 1 Module 2 Module 3 FDA REGULATORY DREAM PMA PMA PMA PMA Approval Submission Submission Submission Submission MARKET CPT code CMS AC
Slide 11: Strong Cash Position with Leading US and European Investors
Strong Cash Position with Leading US and European Investors Cash of €72.5mm with a Runway into Late-2024 Current Shareholder Base (as of 6/30/23) Historical Shareholders International Strategics US Institutional EU Institutional • Robert Taub • Together Partnership • Jürgen Hambrecht 12
Slide 12: Q&A
Q&A